Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Administrative Officer | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,062 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-03 · Tax withholding · Disposed 8,528 · Balance 177,321 F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Row 2 · 2026-06-04 · Sale · Disposed 10,259 · Balance 167,062 F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,832 | $0.00 Strike: $40.34 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 22 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,668 Underlying: Common Stock · 5,832 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 13,231 | $59.80 | $791,213.80 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 7 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,887 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.455 to $60.100, inclusive. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 14,622 | $59.01 | $862,844.22 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 6 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,118 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.455 to $59.445, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,816 | $43.54 | $122,608.64 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 5 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,874 | $38.35 | $301,967.90 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,499 | $44.20 | $243,055.80 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,832 | $32.35 | $188,665.20 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,832 | $40.34 | $235,262.88 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036053 · doc4.xml · derivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036053 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,887 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 01:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,904 | $48.61 | $286,993.44 |
DisclosureSEC source: 0001209191-20-035179 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,887 Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 01:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,402 | $46.33 | $111,287.06 |
DisclosureSEC source: 0001209191-20-035179 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,791 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:15 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 6,252 | $39.49 | $246,891.48 |
DisclosureSEC source: 0001209191-19-046309 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,193 F1 · kind: The sales reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 33,800 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035138 · doc4.xml · derivative · entry 3 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,800 Underlying: Common Stock · 33,800 shares Expires 2029-06-05 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035138 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,445 F2 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,529 | $42.91 | $108,519.39 |
DisclosureSEC source: 0001209191-19-035138 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,845 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 21:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,773 | $47.04 | $224,521.92 |
DisclosureSEC source: 0001209191-18-047108 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,374 F1 · kind: The sales reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.80 to $47.243, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 47,250 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038204 · doc4.xml · derivative · entry 2 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,250 Underlying: Common Stock · 47,250 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:21 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038204 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,147 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2019, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2018 Filed Jun 7, 2018 00:11 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,040 | $33.02 | $67,360.80 |
DisclosureSEC source: 0001209191-18-036186 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,272 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,857 | $0.00 Strike: $25.37 | $0.00 |
DisclosureSEC source: 0001209191-17-061874 · doc4.xml · derivative · entry 6 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,857 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,857 | $40.00 | $314,280.00 |
DisclosureSEC source: 0001209191-17-061874 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,312 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,857 | $25.37 | $199,332.09 |
DisclosureSEC source: 0001209191-17-061874 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,143 | $0.00 Strike: $25.37 | $0.00 |
DisclosureSEC source: 0001209191-17-061874 · doc4.xml · derivative · entry 5 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,857 Underlying: Common Stock · 2,143 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,143 | $40.01 | $85,741.43 |
DisclosureSEC source: 0001209191-17-061874 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,312 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 16, 2017 Filed Nov 20, 2017 23:44 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,143 | $25.37 | $54,367.91 |
DisclosureSEC source: 0001209191-17-061874 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 22:56 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,461 | $36.75 | $127,191.75 |
DisclosureSEC source: 0001209191-17-049503 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,312 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040686 · doc4.xml · derivative · entry 2 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040686 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,773 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2018, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 23:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,877 | $43.32 | $81,313.52 |
DisclosureSEC source: 0001209191-17-038425 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,773 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,979 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · derivative · entry 7 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,979 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,937 | $0.00 Strike: $10.52 | $0.00 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · derivative · entry 6 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,937 shares Expires 2022-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,125 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · derivative · entry 5 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2021-10-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and as to the remaining option shares in successive equal monthly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 21,041 | $50.86 | $1,070,145.26 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,650 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.75 to $51.00, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 11,979 | $10.81 | $129,492.99 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,937 | $10.52 | $62,457.24 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,712 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 15, 2017 Filed May 17, 2017 22:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,125 | $9.25 | $28,906.25 |
DisclosureSEC source: 0001209191-17-033405 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| December 07, 2016 Filed Dec 10, 2016 01:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-16-154561 · doc4.xml · derivative · entry 1 Williams Kristen Marie · CIK 0001296965 · CAO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.